Skip to main content
海昇药业 logo

海昇药业 — Investor Relations & Filings

Ticker · 920656 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 271 across all filing types
Latest filing 2024-02-05 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920656

About 海昇药业

https://www.zcpc.net/

Zhejiang Haisheng Pharmaceutical Co., Ltd. specializes in the research, development, production, and sale of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The company's core product portfolio includes antipyretic and analgesic medications, cardiovascular agents, and various specialty chemical intermediates. It is recognized as a major global supplier of Naproxen and Naproxen Sodium. Haisheng Pharmaceutical maintains rigorous quality control systems compliant with international standards, including Good Manufacturing Practice (GMP) certifications. The company serves a diverse global clientele, providing high-purity chemical components essential for finished dosage form manufacturing. Its technical expertise focuses on chemical synthesis and process optimization to ensure stable supply chains for the pharmaceutical industry.

Recent filings

Filing Released Lang Actions
长江证券承销保荐有限公司关于浙江海昇药业股份有限公司向不特定合格投资者公开发行股票并在北京证券交易所上市超额配售选择权实施情况的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from the underwriting and sponsorship company regarding the implementation of an over-allotment option (greenshoe option) related to a public stock issuance and listing on the Beijing Stock Exchange by Zhejiang Haisheng Pharmaceutical Co., Ltd. It includes specifics about the allotment, exercise of the option, shareholding changes, and compliance with regulatory requirements. The document is not a full financial report but rather a formal verification and disclosure related to capital issuance and share transactions. It does not contain financial statements or earnings data but focuses on the capital raising and share issuance process. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 3234 characters, which is substantive and not a mere announcement or certification, supporting this classification.
2024-02-05 Chinese

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.